Isis And Hybridon Cancel Reciprocal Financial Obligations

Isis Pharmaceuticals and Hybridon have announced the cancellation of the remaining financial obligations related to their Collaboration and License Agreement that the companies completed in May 2001. Under the original agreement, Hybridon owed Isis an additional 4 million shares of Hybridon common stock, payable immediately. Isis owed Hybridon $4.5 million in cash or stock, due Read more about Isis And Hybridon Cancel Reciprocal Financial Obligations[…]

Bentley Extends Collaboration With Pfizer

Bentley Pharmaceuticals, Inc. announced has extended its R&D collaborative agreement with Pfizer Inc. Under the terms of the agreement, Bentley and Pfizer will continue to evaluate certain Pfizer compounds for enhanced delivery. As part of the agreement, Pfizer has access to Bentley’s drug delivery platform through a research license. Pfizer will continue to provide the Read more about Bentley Extends Collaboration With Pfizer[…]

Epimmune And Immuno-designed Molecules Agree License Option

Epimmune Inc. has entered into an evaluation and license option agreement with Immuno-Designed Molecules, S.A. (IDM) for certain cancer antigens for use in IDM’s ex vivo cancer therapy program. Under the terms of the agreement, IDM will have 120 days from the date of the option agreement to evaluate the epitopes and exercise its option Read more about Epimmune And Immuno-designed Molecules Agree License Option[…]

Discovery And Collagenex Collaborate

Discovery Laboratories, Inc. and CollaGenex Pharmaceuticals, Inc. announced a research collaboration to evaluate the combination of their platform technologies for the development of novel respiratory disease therapeutics. The two companies will collaborate on the preclinical evaluation of an aerosolized formulation of Discovery’s humanized lung surfactants combined with CollaGenex‘s IMPACS (Inhibitors of Multiple Proteases and CytokineS) Read more about Discovery And Collagenex Collaborate[…]

Johnson &Johnson’s Epilepsy Drug Leads To Weight Loss

Johnson & Johnson have announced that obese patients lost over 11 percent of their body weight one year after being treated with the company’s anti-epilepsy drug Topamax.The firm is encouraged to continue developing the medicine as a weight-loss medicine.Topamax is currently approved only for treatment of epilepsy, but the New Brunswick, N.J.-based firm is also Read more about Johnson &Johnson’s Epilepsy Drug Leads To Weight Loss[…]

R.P. Scherer To Gain New Drug-Delivery Business

R.P. Scherer Corporation, a subsidiary of Cardinal Health, Inc. has agreed to acquire International Processing Corporation (IPC) of Winchester, Kentucky, in a cash transaction valued at approximately $40 million. Under the agreement, R.P. Scherer will acquire IPC’s contract development and manufacturing business, which uses advanced controlled-release drug delivery manufacturing technology to produce prescription and over-the-counter Read more about R.P. Scherer To Gain New Drug-Delivery Business[…]

Connetics And ALZA Announce Drug Delivery Collaboration

Connetics Corporation has entered into an agreement with ALZA Corporation to develop an advanced drug delivery system for Connetics’ proprietary recombinant human relaxin drug candidate. The development work will focus on applying ALZA’s implantable drug delivery technology, or DUROS system, to expand delivery options for relaxin. The current delivery system for Connetics’ relaxin formulation involves Read more about Connetics And ALZA Announce Drug Delivery Collaboration[…]

Skyepharma Licenses Dermatology Technology

SkyePharma PLC has licensed rights to three topical drug delivery technologies, Crystalip, DermaStick and the ES-Gel system, from Bioglan Pharma PLC. Under the terms of the agreement SkyePharma has paid $9 million in cash and will obtain certain exclusive development and commercial rights in relation to new products from the Crystalip and DermaStick technologies and Read more about Skyepharma Licenses Dermatology Technology[…]